Andrew Connolly is a notable inventor based in San Francisco, CA. He has made significant contributions to the field of biomedical research, particularly in the area of protease-activated receptors. With a total of 2 patents, Connolly's work has the potential to impact therapeutic approaches for various medical conditions.

Latest Patents

Connolly's latest patents include groundbreaking research on protease-activated receptor 3 (PAR3). The first patent discloses cDNAs and genomic DNAs encoding PAR3 from both mouse and human sources. This research highlights the recombinant polypeptides expressed from these cDNAs, which are utilized in screening candidate compounds for their ability to act as agonists or antagonists in the interaction between thrombin and PAR3. Agonists derived from this research are aimed at treating wounds, thrombosis, atherosclerosis, and other thrombin-activated disorders. Conversely, antagonists are designed to control blood coagulation, thereby addressing conditions such as heart attacks and strokes. The second patent similarly focuses on the encoding of PAR3 and its therapeutic applications, emphasizing the importance of antibodies specific to this receptor.

Career Highlights

Andrew Connolly is affiliated with the University of California, where he continues to advance his research in the field of protease-activated receptors. His work has garnered attention for its potential to develop new therapeutic strategies for managing various health conditions.

Collaborations

Connolly has collaborated with esteemed colleagues such as Shaun R. Coughlin and Hiroaki Ishihara. These partnerships have further enriched his research and contributed to the advancement of knowledge in the field.

Conclusion

Andrew Connolly's innovative work in the realm of protease-activated receptors exemplifies the impact of scientific research on medical therapies. His patents and collaborations highlight the importance of continued innovation in addressing complex health challenges.